Results 221 to 230 of about 589,804 (355)

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies [PDF]

, 2016
Khaldoun Almhanna, Thea Kalebic, Cristina Cruz, Jason E. Faris, David P. Ryan, JungAh Jung, Tim Wyant, Adedigbo A. Fasanmade, Wells A. Messersmith, Jordi Rodón   +9 more
openalex   +1 more source

Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer. [PDF]

Front Oncol
Zhou ZZ, Ballard D, Varadkar T, Zhang J, Du Z, George A, Krabacher A, Yengo R, Zhou L, Liu XM.   +9 more
europepmc   +1 more source

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

Advanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang, Huiying Li, Shuodan Huang, Linxuan Zhang, Yan Gao, Ruoran Wang, Xiaoyu Wang, Hélder A. Santos, Zhenyu Yin, Bing Xia   +9 more
wiley   +1 more source

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies [PDF]

, 2016
Michael Flynn, Francesca Zammarchi, Peter Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor S. Barry, François D’Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, John A. Hartley   +17 more
openalex   +1 more source

Global variations in oncology professionals' confidence levels for managing antibody-drug conjugate toxicities: a cross-continental survey. [PDF]

Oncologist
Campione M, Maffezzoli M, Ghose A, Maniam A, Nagpal R, Rescigno P, Buti S, George R, Bambury K, Bambury R, O'Carroll E, Banna GL.   +11 more
europepmc   +1 more source

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

Advanced Functional Materials, EarlyView.
This study demonstrates that cholesterol in messenger RNA‐lipid nanoparticles (mRNA‐LNPs) can be completely replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the
Abhijeet G. Lokras, Saahil S. Baghel, Rune F. Jensen, Aneesh Thakur, Henrik Franzyk, Oskar Thofte, Marco Herrera‐Barrera, Madeleine Landry, Melike Ongun, Ahmad Tami, Marlene P. Thanthrige, Eva Callens, Corinne Beinat, Thomas Rades, Søren R. Paludan, Kristian Riesbeck, Ida Rosenkrands, Dennis Christensen, Gabriel K. Pedersen, Camilla Foged   +19 more
wiley   +1 more source

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM) [PDF]

, 2016
Andrew B. Lassman, Martin J. van den Bent, Hui Gan, David A. Reardon, Priya Kumthekar, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Burt Nabors, Kyriakos P. Papadopoulos, Marta Peñas-Prado, John Simes, Helen Wheeler, Erica Gomez, H.-J. Lee, Lisa Roberts-Rapp, Hao Xiong, Earle Bain, Kyle D. Holen, Ryan Merrell   +19 more
openalex   +1 more source

Antibody-Drug Conjugate Stability Probed by Variable-Temperature Electrospray Ionization Mass Spectrometry. [PDF]

J Am Soc Mass Spectrom
Fiala J, Schuster D, Heck AJR.
europepmc   +1 more source

Transducer Materials Mediated Deep Brain Stimulation in Neurological Disorders

Advanced Functional Materials, EarlyView.
This review discusses advanced transducer materials for improving deep brain stimulation (DBS) in neurological disorders. These materials respond to light, ultrasound, or magnetic fields, enabling precise, less invasive neuromodulation. Their stimulus‐responsive properties enhance neural control and adaptive therapy, paving the way for next‐generation ...
Di Zhao, Zhengyang Cao, Guangjun Zhong, Limin Shi, Junxia Xie, Jianhua Hao   +5 more
wiley   +1 more source

Third-Generation Antibody Drug Conjugates for Cancer Therapy–A Balancing Act [PDF]

, 2016
Mireille Vankemmelbeke, Lindy G. Durrant
openalex   +1 more source